Personalized Medicine in Respiratory Disease

Priyadharshini, V.S.; Teran, Luis M.

doi:10.1016/bs.apcsb.2015.11.008

Cited by 23 publications

(20 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…37,39 Mapping of the proteome is more advanced than the metabolome, however, with drafts of the human and lung proteomes available. 34 Crucially, as with metabolomics, the majority of reported proteomic findings have yet to be validated. 40 One notable difference between metabolomics and proteomics is in the biospecimens used.…”

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

“…34 Studies are hindered by many of the same issues, including sample size, lack of standards for sample collection, handling and storage, multiple incompatible profiling technologies, and underdeveloped analytical methods. 38 Similarly, quantification and identification of proteins is challenging; as with the metabolome, the entire proteome is yet to be characterized.…”

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

“…39 The abundance of proteins in plasma and serum can be both an advantage and a disadvantage, particularly for the measurement of the less abundant, lower molecular weight proteins. 41 The choice of biospecimen may therefore affect the findings 34 and is an important consideration for integrated omics moving forward.…”

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

“…These proteins form the main structural components of all cells and control the majority of their biological functions. 34 One crucial role is as enzymes to catalyze metabolic and signaling pathways; however, it can be difficult to ascertain the endogenous physiological function of these different enzymes because they often exist as part of large networks and are regulated by posttranslational events. Metabolomic profiling of the substrates involved in these reactions can help assign biochemical functions to these enzymes providing access to "a portion of biomolecular space that is inaccessible to genomics and proteomics" 35 and have the potential to identify functionally relevant biological targets.…”

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

See 3 more Smart Citations

Asthma Metabolomics and the Potential for Integrative Omics in Research and the Clinic

Kelly

Dahlin

McGeachie

et al. 2017

Chest

149

135

View full text Add to dashboard Cite

Asthma is a complex disease well-suited to metabolomic profiling, both for the development of novel biomarkers and for the improved understanding of pathophysiology. In this review, we summarize the 21 existing metabolomic studies of asthma in humans, all of which reported significant findings and concluded that individual metabolites and metabolomic profiles measured in exhaled breath condensate, urine, plasma, and serum could identify people with asthma and asthma phenotypes with high discriminatory ability. There was considerable consistency across the studies in terms of the reported biomarkers, regardless of biospecimen, profiling technology, and population age. In particular, acetate, adenosine, alanine, hippurate, succinate, threonine, and trans-aconitate, and pathways relating to hypoxia response, oxidative stress, immunity, inflammation, lipid metabolism and the tricarboxylic acid cycle were all identified as significant in at least two studies. There were also a number of nonreplicated results; however, the literature is not yet sufficiently developed to determine whether these represent spurious findings or reflect the substantial heterogeneity and limited statistical power in the studies and their methods to date. This review highlights the need for additional asthma metabolomic studies to explore these issues, and, further, the need for standardized methods in the way these studies are conducted. We conclude by discussing the potential of translation of these metabolomic findings into clinically useful biomarkers and the crucial role that integrated omics is likely to play in this endeavor.CHEST 2017; 151(2):262-277

show abstract

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Asthma Metabolomics and the Potential for Integrative Omics in Research and the Clinic

Kelly

Dahlin

McGeachie

et al. 2017

Chest

149

135

View full text Add to dashboard Cite

show abstract

“…Studies of common phenotypes, particularly of clinical manifestations, of different diseases, allow knowledge development and cost reduction for precision medicine, and some of these studies are conducted in diseases with pulmonary phenotypes (Priyadharshini and Teran, 2016). …”

Section: Precision Medicine – the Example Of Cystic Fibrosismentioning

confidence: 99%

Personalized or Precision Medicine? The Example of Cystic Fibrosis

Marson

2017

Front. Pharmacol.

View full text Add to dashboard Cite

The advent of the knowledge on human genetics, by the identification of disease-associated variants, culminated in the understanding of human variability. With the genetic knowledge, the specificity of the clinical phenotype and the drug response of each individual were understood. Using the cystic fibrosis (CF) as an example, the new terms that emerged such as personalized medicine and precision medicine can be characterized. The genetic knowledge in CF is broad and the presence of a monogenic disease caused by mutations in the CFTR gene enables the phenotype–genotype association studies (including the response to drugs), considering the wide clinical and laboratory spectrum dependent on the mutual action of genotype, environment, and lifestyle. Regarding the CF disease, personalized medicine is the treatment directed at the symptoms, and this treatment is adjusted depending on the patient’s phenotype. However, more recently, the term precision medicine began to be widely used, although its correct application and understanding are still vague and poorly characterized. In precision medicine, we understand the individual as a response to the interrelation between environment, lifestyle, and genetic factors, which enabled the advent of new therapeutic models, such as conventional drugs adjustment by individual patient dosage and drug type and response, development of new drugs (read through, broker, enhancer, stabilizer, and amplifier compounds), genome editing by homologous recombination, zinc finger nucleases, TALEN (transcription activator-like effector nuclease), CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated endonuclease 9), and gene therapy. Thus, we introduced the terms personalized medicine and precision medicine based on the CF.

show abstract

Searching for biomarkers of chronic obstructive pulmonary disease using proteomics: The current state

et al. 2018

View full text Add to dashboard Cite

Detection of proteins which may be potential biomarkers of disorders represents a big step forward in understanding the molecular mechanisms that underlie pathological processes. In this context proteomics plays the important role of opening a path for the identification of molecular signatures that can potentially assist in early diagnosis of several clinical disturbances. Aim of this report is to provide an overview of the wide variety of proteomic strategies that have been applied to the investigation of chronic obstructive pulmonary disease (COPD), a severe disorder that causes an irreversible damage to the lungs and for which there is no cure yet. The results in this area published over the past decade show that proteomics indeed has the ability of monitoring alterations in expression profiles of proteins from fluids/tissues of patients affected by COPD and healthy controls. However, these data also suggest that proteomics, while being an attractive tool for the identification of novel pathological mediators of COPD, remains a technique mainly generated and developed in research laboratories. Great efforts dedicated to the validation of these biological signatures will result in the proof of their clinical utility.

show abstract

Personalized Medicine in Respiratory Disease

Cited by 23 publications

References 119 publications

Asthma Metabolomics and the Potential for Integrative Omics in Research and the Clinic

Asthma Metabolomics and the Potential for Integrative Omics in Research and the Clinic

Personalized or Precision Medicine? The Example of Cystic Fibrosis

Searching for biomarkers of chronic obstructive pulmonary disease using proteomics: The current state

Contact Info

Product

Resources

About